The Shingrix vaccine, a highly effective solution for preventing shingles, has recently become available in Australia, offering significant protection against the painful condition caused by the reactivation of the varicella-zoster virus. Shingles, also known as herpes zoster, typically affects older adults and individuals with weakened immune systems, leading to a painful rash and, in some cases, long-term nerve pain known as postherpetic neuralgia. Shingrix, a recombinant zoster vaccine, has demonstrated over 90% efficacy in preventing shingles and its complications in clinical trials, making it a major advancement in public health.

The availability of Shingrix in Australia marks a significant milestone, as it provides a more effective alternative to previous vaccines like Zostavax. Administered in two doses, Shingrix is recommended for adults aged 50 years and older, as well as those at increased risk of shingles due to immunosuppression. Its introduction aligns with efforts to reduce the healthcare burden associated with shingles, which can lead to hospitalisations and reduced quality of life. Australians now have access to this powerful preventive tool, which will play a crucial role in protecting the aging population and minimizing the long-term effects of shingles-related complications.

Please speak to your doctor to find out if you are eligible for Shingrix.